Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Celgene and Acceleron commence new cancer drug trial

Celgene and Acceleron commence new cancer drug trial

3rd June 2011

Celgene is allying with Acceleron Pharma on the commencement of a new clinical trial for a developmental lung cancer treatment.

The companies are beginning the first part of a phase II/III study of ACE-011 for treating chemotherapy-induced anaemia in patients with metastatic non-small cell lung cancer.

It will begin with a dose-ranging study for the treatment, before leading into a placebo-controlled comparative trial among patients treated with first-line platinum-based chemotherapeutic regimens.

The initiation of this trial will trigger a $7 million (4.29 million pounds) milestone payment from Celgene to Acceleron as part of their ongoing collaboration agreement.

Dr Matthew Sherman, chief medical officer of Acceleron, said: "There is enormous unmet medical need for a safe and effective alternative to erythropoiesis-stimulating agents for the treatment for chemotherapy-induced anaemia."

Last month, Celgene published its financial report for the first quarter of 2011, during which it experienced a record-breaking performance in terms of revenue.ADNFCR-8000103-ID-800566406-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.